8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



Date of Report (Date of earliest event reported)        September 8, 2005
                                                --------------------------------


                           Molecular Diagnostics, Inc.
- --------------------------------------------------------------------------------
               (Exact name of registrant as specified in charter)

       Delaware                      0-935                      36-4296006
- --------------------------------------------------------------------------------
(State or other jurisdiction      (Commission                (IRS Employer
    of incorporation)             File Number)              Identification No.)


414 North Orleans Street, Suite 502, Chicago, Illinois             60610
- --------------------------------------------------------------------------------
       (Address of principal executive offices)                  (Zip Code)


Registrant's telephone number, including area code         (312) 222-9550
                                                   -----------------------------

                                 Not Applicable
- --------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)






      Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ]   Written communications pursuant to Rule 425 under the Securities Act
      (17 CFR 230.425)

[ ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

[ ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

[ ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))



                                TABLE OF CONTENTS

                                    FORM 8-K




Item                                                                                 Page
- ----                                                                                 ----
                                                                              
Item 5.02    Departure of Directors or Principal Officers; Election of Directors;

             Appointment of Principal Officers                                         1

Item 9.01    Financial Statements and Exhibits                                         1

Signature                                                                              1











Item 5.02 Departure of Directors or Principal Officers; Election of Directors;
          Appointment of Principal Officers

      On September 8, 2005, Robert McCullough, Jr. accepted the nomination of
the Board of Directors to become a director of the Company. The Board had
nominated Mr. McCullough on August 29, 2005, to become effective upon Mr.
McCullough's acceptance. Any committee appointments will be announced upon board
approval.

      Mr. McCullough has an MBA in finance and is a Certified Public Accountant.
He was an executive at Ernst & Young (formerly Ernst & Whinney), and served as
CFO at two privately-owned health care companies. Mr. McCullough has been in the
investment business for the last 18 years as a Portfolio Manager/Security
Analyst, and currently as President of Summitcrest Capital Management. Mr.
McCullough has been an investor in Molecular Diagnostics since 2001.


Item 9.01 Financial Statements and Exhibits

          (d)      Exhibits

          99.1     Press Release dated September 8, 2005


                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                            Molecular Diagnostics, Inc.



Dated: September 8, 2005                    By: /s/ David Weissberg, M.D.
                                                --------------------------------
                                                David Weissberg, M.D.
                                                Chief Executive Officer

EX-99.1

[Logo of Molecular Diagnostics]

                                                                   PRESS RELEASE
                                                           For immediate release

                     MOLECULAR DIAGNOSTICS ADDS TO ITS BOARD

CHICAGO, IL, September 8, 2005 - Molecular Diagnostics, Inc. (OTCBB: MCDG.OB)
announced the addition of Robert McCullough, Jr. to the Board of Directors. The
Board had nominated Mr. McCullough on August 29, 2005, to become effective upon
Mr. McCullough's acceptance.

      Mr. McCullough has an MBA in finance and is a Certified Public Accountant.
He was an executive at Ernst & Young, (formerly Ernst & Whinney), and served as
CFO at two privately owned Health Care companies. Mr. McCullough has been in the
investment business for the last 18 years as Portfolio Manager/Security Analyst,
and currently as President of Summitcrest Capital Management. Mr. McCullough
brings years of financial controls experience in the healthcare sector and most
recently as an Analyst/Portfolio Manager. Mr. McCullough has been an investor in
Molecular Diagnostics since 2001.

CEO Dr. David Weissberg said "We are delighted to have Bob McCullough's
financial experience in the health care sector. It can only assist the solid
efforts that Molecular's financial staff has accomplished so far in our
restructuring, and Bob's input should help us to rapidly conclude this process.
In addition, Bob's investment background and his focus in the health care sector
will be helpful to our subsequent financing efforts, and in addressing the
bio-tech investment community in the Bay Area."

Bob McCullough said, "I am very pleased to be invited to work on Molecular's
Board and to help with this most exciting turn-around. As an investor in
Molecular Diagnostics, I have always been a firm proponent and supporter of the
technology, even through all the hard times. The new investors embodied in the
likes of David Weissberg have brought renewed energy and commitment to make sure
this technology gets to market. The team I see being assembled and the resources
being brought to bear are exciting, and indicate to me that we will be able to
move the company forward aggressively. The Company's technology should make very
significant beneficial changes in the diagnosis of cervical cancer world wide,
thereby playing an important role in reducing the death rate from this disease
while dramatically lowering the cost to diagnose and treat this disease."

About Molecular Diagnostics, Inc.
Molecular Diagnostics develops cost-effective cancer screening systems, which
can be utilized in a laboratory or at the point-of-care, to assist in the early
detection of cervical, gastrointestinal, and other cancers. The InPath(TM)
System is being developed to provide medical practitioners with a highly
accurate, low-cost, cervical cancer screening system that can be integrated into
existing medical models or at the point-of-care.

More information is available at: www.Molecular-Dx.com
                                  --------------------

Certain statements in this release are forward-looking. These statements are
based on Molecular Diagnostics' current expectations and involve many risks and
uncertainties, such as the company's inability to obtain sufficient financing,
the possibility that clinical trials will not substantiate Molecular
Diagnostics' expectations with respect to the InPath(TM) System, and other
factors set forth in reports and documents filed by Molecular Diagnostics with
the Securities and Exchange Commission. Actual results may differ materially
from Molecular Diagnostic's current expectations depending upon a number of
factors affecting the Company's business. These factors include, among others,
risks and uncertainties detailed in the Company's periodic public filings with
the Securities and Exchange Commission, including but not limited to the
Company's Annual Report on Form 10-KSB for the year ended December 31, 2004 and
its Quarterly Reports on Form 10-QSB for the quarters ended March 31, 2005 and
June 30, 2005. Except as expressly required by law, Molecular Diagnostics
undertakes no obligation to publicly update or revise any forward-looking
statements contained herein.

Contacts:

Director Communications
Gene Martineau
(212)348-1852
ebm@interport.net
- -----------------